Inhale the Future: Embracing the Next Generation of Inhalable


Nanomedicine Technologies Introduction

Unmet Medical Need of Respiratory Diseases



Promises of Inhalable Nanomedicines

- Enhanced drug delivery efficiency into the lungs via inhalation
- · Nanotechnology-mediated enhanced treatment efficacy




Challenges in Inhalable Nanomedicine Development & Commercialization

LKS Faculty of Medicine

Department of Pharmacology & Pharmacy 香港大學藥理及藥劑學系 Advanced Biomedical Instrumentation Centre

- Nanoparticles cannot directly deposit into the lungs due to low inertia
- Precise particle size control of aerosols is required for drug delivery into lungs via inhalation




Key Invention Innovations

- A scalable and continuous manufacturing platform for fabricating inhalable nanomedicines
- Tunable particle size for deep lungnanoparticle delivery
- · Integration of nanotechnology with inhaled drug delivery for enhanced treatment efficacy against respiratory diseases
- Applicable to patients with varying degreees of pulmonary function impairment (e.g., COPD & lung cancer)

Methodology

A continuous manufacturing platform for inhalable nanoagglomerate powder was developed by integrating flash nanoprecipitation (FNP), in-situ thermal gelation and spray drying.



Applications


The invention has been harnessed to fabricate inhalable paclitaxel and remdesivir nanoagglomerate powders with great therapeutic potential for treating lung cancer and COVID-19.

It can expetide the adoption of advanced manufacturing in line with Industry 4.0, accerelating the development of inhalable nanomedicines to address current medical gaps.

Potential Future Applications

The invention can be extended to manufacture nanoagglomerate nasal powders for nose-to-brain delivery of neurotherapeutics (e.g., fingolimod for ischemic stroke).

Orally Inhalable Paclitaxel Nanoagglomerate Powder for Lung Cancer Treatment



Acknowledgements

Health@InnoHK programme, Innovation and Technology Commission, HKSAR Government Health and Medical Research Fund (Project number: 08191956), Health Bureau, HKSAR Government